• Articles
    • Views
    SUBSCRIBER

    Tony Farnham

    Tony Farnham is a financial markets veteran and Analyst/Financial Writer at The Capital Network.

Author's Posts

  • Carly Holdings’ EV Trial targets aspiring EV buyers

    Most consumers love ‘try before you buy’ opportunities, especially when the goods or services involved are big ticket items laden with new technology not yet fully understood by the general population. Such test runs are effectively a way for potential purchasers to undertake some due diligence on a product before deciding to take the plunge

    Read More
    Public
  • Careteq further penetrates its large and growing addressable market

    Addressing industry thematics of cloud-based computing and technology disruption and the rapid aging of Western populations, Careteq (ASX:CTQ ) has released FY23 results that  demonstrate it is penetrating these addressable markets and is moving closer to creating a sustainable business.  Its suite of leading cloud-based assistive living technology solutions, encompassing intelligent sensors and devices, materially

    Read More
    Public
  • Proteomics’ PromarkerD test enters the lucrative US market

    Successful early diagnosis of diabetic kidney disease (DKD) delivers a win-win-win situation for the medical professionals who treat this disease, its sufferers and the cost base of any country’s health system. Doctors would gain access to speedier diagnosis, opening the way for them to deliver more efficacious treatment decisions that improve clinical outcomes for patients,

    Read More
    Public
  • 4DMedical’s tech platform now unambiguously in early commercialisation

    Back in the 1970s the world marvelled as the then revolutionary CT scan and nuclear medicine technologies that allowed health care professionals to gain never-before-seen insights into patients’ diseased lungs. The 3D pictures they provided were high resolution images that were a vast improvement on the 2D (x-rays) and 1D (spirometry) tests previously available. Fast

    Read More
    Public
  • Proteomics’ early detection test for endometriosis potentially a game changer

    Endometriosis is a chronic disease where tissue similar to the lining of the uterus grows outside the uterus. Women are susceptible to this disease over a significant portion of their lives, starting with their first menstrual period, extending through until menopause. For all the advances in medical science, the disease has no known cure. Even

    Read More
    Public
  • IRIS Metals gains $3.5 million funding for US lithium

    IRIS Metals (ASX: IR1) announced an investment of $1,500,000 from the Electrification and Decarbonization AIE LP Fund, managed by Waratah Capital Advisors. The placement saw 1,500,000 shares issued at $1 per share with a bonus 750,000 options with an exercise price of $1.50 two years from the date of issue. In addition to the $1,500,000

    Read More
    Public
  • Live Verdure: A unique health and wellness company on the rise

    Since the dawn of time, most people have wanted to live, look, feel and achieve our best for as long as possible. But in a classic ‘please sir can I have some more’ moment, many also want the abovementioned deliverables to be much more than that possible from doing the basics right, namely eating and

    Read More
    Public
  • The age of mRNA therapeutics is now – with exosomes

    mRNA therapeutics are now expected to become the third major class of drugs. But converting their promise into reality, just like what happened with electric vehicles, is not without technical challenges. In the case of electric vehicles, their sales only really took off once the complex new battery technologies which enabled high-performance together with extended

    Read More
    Public
  • COG Financial doubles profit as low interest rates drive borrowing

    Asset finance broking/aggregation group and SME lender COG Financial Services Limited (ASX: COG) reported an underlying Net Profit After Tax and before Amortisation (NPATA) of $10.1m in its H1 FY21 (the six months ended December 2020). This was more than double the equivalent underlying profit figures for both the previous corresponding period (pcp) and the

    Read More
    Public